Austwick's addition to Verona Pharma's board, with his extensive biopharmaceutical experience, is viewed positively. His expertise is anticipated to be beneficial for the potential launch of ensifentrine.
Verona Pharma's debt usage seems safe given sufficient short-term liquidity. Concerns over capital raise loom due to a lack of significant revenue and history of cash burn. Balance sheet isn't the only investment risk; identified warning signs also exist.
維羅納製藥股票討論區
follow for daily watchlist ⭐️
In reaction to earnings/guidance:
• $富樂客(FL.US)$ +19.7%, $BILL Holdings(BILL.US)$ +18.1% (also names new COO), $巴克爾(BKE.US)$ +1.7%
Other news:
• $Axsome Therapeutics(AXSM.US)$ +33.8% (announces FDA approval of AUVELITY the first and only oral nmda receptor antagonist for the treatment of major depressive disorder in adults)
• $SpringWorks Therapeutics(SWTX.US)$ +4.9% (late-breaking oral presentation of phase 3 DeFi da...
暫無評論